News
InnoCare receives China NMPA approval to conduct clinical trial of a novel B7-H3 targeted ADC ICP-B794: Beijing Monday, July 7, 2025, 15:00 Hrs [IST] InnoCare Pharma, a leading bi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback